Straits Times Index
3,276.17 -11.58 (-0.35%) Nikkei
37,780.35 +151.87 (+0.40%) Hang Seng
17,595.93 +311.39 (+1.80%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,409.65 +127.74 (+0.20%) CMC Crypto 200
1,392.04 +9.47 (+0.68%)
Sanofi (SNY)
After hours:
- Insider Monkey
20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Zacks
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
- Reuters
UPDATE 2-Sanofi profit slips on generic competition and currency effects
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
